Is AGEN or ACHV more profitable?

Agenus has a net margin of 50.49% compared to Achieve Life Sciences' net margin of 0.00%. Agenus' return on equity of -31.66% beat Achieve Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Agenus 50.49% -31.66% 42.71% Achieve Life Sciences N/A -193.49% -111.88%

Does the media prefer AGEN or ACHV?

In the previous week, Achieve Life Sciences had 7 more articles in the media than Agenus. MarketBeat recorded 8 mentions for Achieve Life Sciences and 1 mentions for Agenus. Agenus' average media sentiment score of 0.90 beat Achieve Life Sciences' score of -0.03 indicating that Agenus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Achieve Life Sciences 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, CBIO or AGEN?

Agenus has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Crescent Biopharma $10.84M 44.49 -$153.94M -$10.91 N/A Agenus $114.20M 1.12 $120K $1.59 1.93

Does the media refer more to CBIO or AGEN?

In the previous week, Crescent Biopharma had 7 more articles in the media than Agenus. MarketBeat recorded 8 mentions for Crescent Biopharma and 1 mentions for Agenus. Agenus' average media sentiment score of 0.90 beat Crescent Biopharma's score of -1.29 indicating that Agenus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Agenus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AGEN or MYGN more profitable?

Agenus has a net margin of 50.49% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat Agenus' return on equity. Company Net Margins Return on Equity Return on Assets Agenus 50.49% -31.66% 42.71% Myriad Genetics -48.24% -8.51% -4.48%

Does the media prefer AGEN or MYGN?

In the previous week, Myriad Genetics had 2 more articles in the media than Agenus. MarketBeat recorded 3 mentions for Myriad Genetics and 1 mentions for Agenus. Agenus' average media sentiment score of 0.90 beat Myriad Genetics' score of 0.04 indicating that Agenus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Myriad Genetics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, AGEN or VSTM?

Agenus has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Agenus $114.20M 1.12 $120K $1.59 1.93 Verastem $30.91M 11.97 -$209.47M -$2.70 N/A

Is AGEN or VSTM more profitable?

Agenus has a net margin of 50.49% compared to Verastem's net margin of -391.17%. Agenus' return on equity of -31.66% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Agenus 50.49% -31.66% 42.71% Verastem -391.17% -486.40% -91.56%

Does the media prefer AGEN or VSTM?

In the previous week, Verastem had 9 more articles in the media than Agenus. MarketBeat recorded 10 mentions for Verastem and 1 mentions for Agenus. Agenus' average media sentiment score of 0.90 beat Verastem's score of -0.02 indicating that Agenus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verastem 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Agenus (AGEN) Competitors

$3.07 +0.03 (+0.99%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$3.08 +0.01 (+0.29%)

As of 07:50 AM Eastern

Compare

AGEN vs. ACHV, CBIO, MYGN, EBS, and VSTM

Should you buy Agenus stock or one of its competitors? MarketBeat compares Agenus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Agenus include Achieve Life Sciences (ACHV), Crescent Biopharma (CBIO), Myriad Genetics (MYGN), Emergent Biosolutions (EBS), and Verastem (VSTM). These companies are all part of the "biotechnology" industry.

How does Agenus compare to Achieve Life Sciences?

Agenus (NASDAQ:AGEN) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

Agenus currently has a consensus target price of $23.00, suggesting a potential upside of 649.19%. Achieve Life Sciences has a consensus target price of $14.67, suggesting a potential upside of 192.75%. Given Agenus' higher possible upside, equities analysts clearly believe Agenus is more favorable than Achieve Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Achieve Life Sciences had 7 more articles in the media than Agenus. MarketBeat recorded 8 mentions for Achieve Life Sciences and 1 mentions for Agenus. Agenus' average media sentiment score of 0.90 beat Achieve Life Sciences' score of -0.03 indicating that Agenus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Achieve Life Sciences	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Agenus has a net margin of 50.49% compared to Achieve Life Sciences' net margin of 0.00%. Agenus' return on equity of -31.66% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	50.49%	-31.66%	42.71%
Achieve Life Sciences	N/A	-193.49%	-111.88%

Agenus has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	1.12	$120K	$1.59	1.93
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A

61.5% of Agenus shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 6.5% of Agenus shares are owned by company insiders. Comparatively, 1.8% of Achieve Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Agenus has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.27, indicating that its share price is 127% more volatile than the broader market.

Summary

Agenus beats Achieve Life Sciences on 11 of the 16 factors compared between the two stocks.

How does Agenus compare to Crescent Biopharma?

Crescent Biopharma (NASDAQ:CBIO) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 8.7% of Crescent Biopharma shares are held by insiders. Comparatively, 6.5% of Agenus shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Crescent Biopharma had 7 more articles in the media than Agenus. MarketBeat recorded 8 mentions for Crescent Biopharma and 1 mentions for Agenus. Agenus' average media sentiment score of 0.90 beat Crescent Biopharma's score of -1.29 indicating that Agenus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Agenus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agenus has a net margin of 50.49% compared to Crescent Biopharma's net margin of 0.00%. Agenus' return on equity of -31.66% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-103.44%	-88.19%
Agenus	50.49%	-31.66%	42.71%

Crescent Biopharma has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market. Comparatively, Agenus has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market.

Agenus has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	44.49	-$153.94M	-$10.91	N/A
Agenus	$114.20M	1.12	$120K	$1.59	1.93

Crescent Biopharma presently has a consensus target price of $29.00, indicating a potential upside of 65.71%. Agenus has a consensus target price of $23.00, indicating a potential upside of 649.19%. Given Agenus' higher probable upside, analysts clearly believe Agenus is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Agenus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Agenus beats Crescent Biopharma on 10 of the 17 factors compared between the two stocks.

How does Agenus compare to Myriad Genetics?

Agenus (NASDAQ:AGEN) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Agenus has higher earnings, but lower revenue than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	1.12	$120K	$1.59	1.93
Myriad Genetics	$824.50M	0.53	-$365.90M	-$4.30	N/A

Agenus has a net margin of 50.49% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	50.49%	-31.66%	42.71%
Myriad Genetics	-48.24%	-8.51%	-4.48%

61.5% of Agenus shares are owned by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are owned by institutional investors. 6.5% of Agenus shares are owned by company insiders. Comparatively, 1.9% of Myriad Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Agenus currently has a consensus target price of $23.00, indicating a potential upside of 649.19%. Myriad Genetics has a consensus target price of $6.50, indicating a potential upside of 39.48%. Given Agenus' higher probable upside, research analysts clearly believe Agenus is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Myriad Genetics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Agenus has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.73, suggesting that its stock price is 73% more volatile than the broader market.

In the previous week, Myriad Genetics had 2 more articles in the media than Agenus. MarketBeat recorded 3 mentions for Myriad Genetics and 1 mentions for Agenus. Agenus' average media sentiment score of 0.90 beat Myriad Genetics' score of 0.04 indicating that Agenus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Myriad Genetics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Agenus beats Myriad Genetics on 9 of the 14 factors compared between the two stocks.

How does Agenus compare to Emergent Biosolutions?

Emergent Biosolutions (NYSE:EBS) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Emergent Biosolutions has a beta of 2.33, indicating that its stock price is 133% more volatile than the broader market. Comparatively, Agenus has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market.

In the previous week, Agenus had 1 more articles in the media than Emergent Biosolutions. MarketBeat recorded 1 mentions for Agenus and 0 mentions for Emergent Biosolutions. Agenus' average media sentiment score of 0.90 beat Emergent Biosolutions' score of 0.00 indicating that Agenus is being referred to more favorably in the news media.

Company	Overall Sentiment
Emergent Biosolutions	Neutral
Agenus	Positive

Emergent Biosolutions has higher revenue and earnings than Agenus. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$742.90M	0.56	$52.60M	-$0.28	N/A
Agenus	$114.20M	1.12	$120K	$1.59	1.93

Agenus has a net margin of 50.49% compared to Emergent Biosolutions' net margin of -1.27%. Emergent Biosolutions' return on equity of 10.76% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-1.27%	10.76%	4.22%
Agenus	50.49%	-31.66%	42.71%

Emergent Biosolutions presently has a consensus target price of $12.00, suggesting a potential upside of 50.00%. Agenus has a consensus target price of $23.00, suggesting a potential upside of 649.19%. Given Agenus' higher possible upside, analysts plainly believe Agenus is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Agenus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

78.4% of Emergent Biosolutions shares are owned by institutional investors. Comparatively, 61.5% of Agenus shares are owned by institutional investors. 6.0% of Emergent Biosolutions shares are owned by insiders. Comparatively, 6.5% of Agenus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Agenus beats Emergent Biosolutions on 9 of the 16 factors compared between the two stocks.

How does Agenus compare to Verastem?

Agenus (NASDAQ:AGEN) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

In the previous week, Verastem had 9 more articles in the media than Agenus. MarketBeat recorded 10 mentions for Verastem and 1 mentions for Agenus. Agenus' average media sentiment score of 0.90 beat Verastem's score of -0.02 indicating that Agenus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verastem	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Agenus has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, Verastem has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Agenus has a net margin of 50.49% compared to Verastem's net margin of -391.17%. Agenus' return on equity of -31.66% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	50.49%	-31.66%	42.71%
Verastem	-391.17%	-486.40%	-91.56%

Agenus presently has a consensus target price of $23.00, indicating a potential upside of 649.19%. Verastem has a consensus target price of $14.20, indicating a potential upside of 237.29%. Given Agenus' higher probable upside, equities analysts clearly believe Agenus is more favorable than Verastem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Agenus has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	1.12	$120K	$1.59	1.93
Verastem	$30.91M	11.97	-$209.47M	-$2.70	N/A

61.5% of Agenus shares are owned by institutional investors. Comparatively, 88.4% of Verastem shares are owned by institutional investors. 6.5% of Agenus shares are owned by company insiders. Comparatively, 1.9% of Verastem shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Agenus beats Verastem on 11 of the 17 factors compared between the two stocks.

Get Agenus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGEN vs. The Competition

Export

Metric	Agenus	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$126.59M	$3.45B	$6.45B	$12.38B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	1.93	19.75	24.66	23.99
Price / Sales	1.12	330.35	526.33	107.23
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	-0.38	8.29	10.72	6.50
Net Income	$120K	$23.85M	$3.56B	$336.88M
7 Day Performance	3.72%	2.87%	0.94%	-0.16%
1 Month Performance	-1.29%	2.19%	0.36%	0.76%
1 Year Performance	-38.60%	55.48%	29.67%	28.49%

Agenus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGEN Agenus	2.8417 of 5 stars	$3.07 +1.0%	$23.00 +649.2%	-36.0%	$126.59M	$114.20M	1.93	440
ACHV Achieve Life Sciences	2.5721 of 5 stars	$5.10 +5.2%	$14.67 +187.6%	+30.5%	$497.90M	N/A	N/A	20	Analyst Forecast
CBIO Crescent Biopharma	1.441 of 5 stars	$17.57 -0.7%	$29.00 +65.1%	+14.4%	$487.48M	$10.84M	N/A	50	News Coverage Negative News Insider Trade Gap Down
MYGN Myriad Genetics	2.4896 of 5 stars	$4.50 -0.9%	$6.50 +44.4%	-4.1%	$428.80M	$824.50M	N/A	2,700	News Coverage
EBS Emergent Biosolutions	1.8317 of 5 stars	$7.86 -1.7%	$12.00 +52.6%	+22.7%	$412.77M	$742.90M	N/A	2,420

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGEN) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Agenus (AGEN) Competitors

AGEN vs. ACHV, CBIO, MYGN, EBS, and VSTM

How does Agenus compare to Achieve Life Sciences?

Summary

How does Agenus compare to Crescent Biopharma?

Summary

How does Agenus compare to Myriad Genetics?

Summary

How does Agenus compare to Emergent Biosolutions?

Summary

How does Agenus compare to Verastem?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGEN vs. The Competition

Agenus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Agenus (AGEN) Competitors

AGEN vs. ACHV, CBIO, MYGN, EBS, and VSTM

How does Agenus compare to Achieve Life Sciences?

Do analysts recommend AGEN or ACHV?

Does the media prefer AGEN or ACHV?

Is AGEN or ACHV more profitable?

Which has preferable earnings and valuation, AGEN or ACHV?

Do institutionals & insiders have more ownership in AGEN or ACHV?

Which has more volatility & risk, AGEN or ACHV?

Summary

How does Agenus compare to Crescent Biopharma?

Do insiders and institutionals believe in CBIO or AGEN?

Does the media refer more to CBIO or AGEN?

Is CBIO or AGEN more profitable?

Which has more risk & volatility, CBIO or AGEN?

Which has stronger earnings & valuation, CBIO or AGEN?

Do analysts prefer CBIO or AGEN?

Summary

How does Agenus compare to Myriad Genetics?

Which has preferable earnings & valuation, AGEN or MYGN?

Is AGEN or MYGN more profitable?

Do institutionals and insiders have more ownership in AGEN or MYGN?

Do analysts rate AGEN or MYGN?

Which has more volatility & risk, AGEN or MYGN?

Does the media prefer AGEN or MYGN?

Summary

How does Agenus compare to Emergent Biosolutions?

Which has more volatility and risk, EBS or AGEN?

Does the media refer more to EBS or AGEN?

Which has preferable valuation and earnings, EBS or AGEN?

Is EBS or AGEN more profitable?

Do analysts recommend EBS or AGEN?

Do insiders & institutionals hold more shares of EBS or AGEN?

Summary

How does Agenus compare to Verastem?

Does the media prefer AGEN or VSTM?

Which has more volatility and risk, AGEN or VSTM?

Is AGEN or VSTM more profitable?

Do analysts prefer AGEN or VSTM?

Which has better valuation & earnings, AGEN or VSTM?

Do insiders and institutionals have more ownership in AGEN or VSTM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGEN vs. The Competition

Agenus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools